Inflammation to cancer: The molecular biology in the pancreas (review)

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 1747-1754

  Ling, Sunbin ^a   Feng, Tingting ^a   Jia, Kaiqi ^a   Tian, Yu ^a   Li, Yan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Inflammation; K ras; Nuclear factor B; Pancreatic cancer; Proinflammatory cytokines; Reactive oxygen species; Serine protease inhibitor kazal type 1

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; APROTININ; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE PEROXIDASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; LEUKOTRIENE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THROMBOXANE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CELL PROLIFERATION; CHRONIC PANCREATITIS; DNA FRAGMENTATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MRNA EXPRESSION ASSAY; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

EID: 84898880402     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2003     Document Type: Article

References (139)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Batty GD, Kivimaki M, Morrison D, et al: Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev 18: 673-675, 2009.
3. Landi S: Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 681: 299-307, 2009.
4. Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209, 2006.
5. Genkinger JM, Spiegelman D, Anderson KE, et al: Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 18: 765-776, 2009.
6. Hassan MM, Bondy ML, Wolff RA, et al: Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102: 2696-2707, 2007.
7. Peek RM, Jr. and Crabtree JE: Helicobacter infection and gastric neoplasia. J Pathol 208: 233-248, 2006.
8. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535, 2001.
9. Canavan C, Abrams KR and Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23: 1097-1104, 2006.
10. Solaymani-Dodaran M, Logan RF, West J, Card T and Coupland C: Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53: 1070-1074, 2004.
11. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
12. Ekbom A, McLaughlin JK, Karlsson BM, et al: Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 86: 625-627, 1994.
13. Talamini G, Falconi M, Bassi C, et al: Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 94: 1253-1260, 1999.
14. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328: 1433-1437, 1993.
15. Maisonneuve P, Lowenfels AB, Müllhaupt B, et al: Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut 54: 510-514, 2005.
16. Doll R, Peto R, Hall E, Wheatley K and Gray R: Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ 309: 911-918, 1994.
17. Bracci PM, Wang F, Hassan MM, Gupta S, Li D and Holly EA: Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 20: 1723-1731, 2009.
18. Bansal P and Sonnenberg A: Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109: 247-251, 1995.
19. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J and Whitcomb DC: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442-446, 1997.
20. Chari ST, Mohan V, Pitchumoni CS, Viswanathan M, Madanagopalan N and Lowenfels AB: Risk of pancreatic carcinoma in tropical calcifying pancreatitis: an epidemiologic study. Pancreas 9: 62-66, 1994.
21. Ji B, Tsou L, Wang H, Gaiser S, et al: Ras activity levels control the development of pancreatic diseases. Gastroenterology 137: 1072-1082, 2009.
22. Wang Z, Ali S, Banerjee S, et al: Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 228: 556-562, 2013.
23. Bishop M, Xenoulis P and Steiner JM: Association between this SPINK1 variant and clinically detectable pancreatitis. J Vet Intern Med 27: 427-428, 2013.
24. Hucl T, Jesnowski R, Pfützer RH, Elsässer HP and Löhr M: SPINK1 variants in young-onset pancreatic cancer. J Gastroenterol 42: 599, 2007.
25. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S and Beger HG: Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25: 26-30, 2002.
26. Vinokurova LV, Berezina OI, Drozdov VN, Petrakov AV and Nilova TV: Nitric oxide and indicators of oxidative stress in patients with exacerbation of chronic pancreatitis. Eksp Klin Gastroenterol 2: 75-81, 2011 (In Russian).
27. Bernards A and Settleman J: GAP control: regulating the regulators of small GTPases. Trends Cell Biol 14: 377-385, 2004.
28. Voice JK, Klemke RL, Le A and Jackson JH: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 274: 17164-17170, 1999.
29. Maekawa M, Nishida E and Tanoue T: Identification of the anti-proliferative protein Tob as a MAPK substrate. J Biol Chem 277: 37783-37787, 2002.
30. Roux PP, Ballif BA, Anjum R, Gygi SP and Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494, 2004.
31. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD and Downward J: Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15: 2442-2451, 1996.
32. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
33. Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89: 457-467, 1997.
34. Mulligan NJ, Yang S, Andry C, Klein M, and O'Brien MJ: The role of p21ras in pancreatic neoplasia and chronic pancreatitis. Hum Pathol 30: 602-610, 1999.
35. Mu DQ, Peng YS, and Xu QJ: Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 10: 471-475, 2004.
36. Guerra C, Schuhmacher AJ, Cañamero M, et al: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302, 2007.
37. Logsdon CD and Ji B: Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol 7 (11 Suppl): S40-S43, 2009.
38. Guerra C, Collado M, Navas C, et al: Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19: 728-739, 2011.
39. Collado M and Serrano M: Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51-57, 2010.
40. Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22: 318-330, 2012.
41. Ardito CM, Grüner BM, Takeuchi KK, et al: EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22: 304-317, 2012.
42. Wang Z, Banerjee S, Ahmad A, et al: Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One 6: e20537, 2011.
43. Daniluk J, Liu Y, Deng D, et al: An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519-1528, 2012.
44. Friday BB and Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys Acta 1756: 127-144, 2005.
45. Kamisawa T, Takuma K, Tabata T, Egawa N and Yamaguchi T: Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice. Hepatogastroenterology 58: 174-176, 2011.
46. Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470: M69-M78, 2000.
47. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
48. Diaz A, Chepenik KP, Korn JH, Reginato AM and Jimenez SA: Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241: 222-229, 1998.
49. Aoki H, Ohnishi H, Hama K, et al: Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol 292: C259-C268, 2007.
50. Koliopanos A, Friess H, Kleeff J, Roggo A, Zimmermann A and Büchler MW: Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus. Digestion 64: 240-247, 2001.
51. O'Brien G, Shields CJ, Winter DC, Dillon JP, Kirwan WO and Redmond HP: Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury. Hepatobiliary Pancreat Dis Int 4: 126-129, 2005.
52. Albazaz R, Verbeke CS, Rahman SH and McMahon MJ: Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 5: 361-369, 2005.
53. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F and Saisho H: Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 94: 1565-1573, 2002.
54. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59: 4356-4362, 1999.
55. Kokawa A, Kondo H, Gotoda T, et al: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91: 333-338, 2001.
56. Hillion J, Smail SS, Di Cello F, et al: The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology 12: 372-379, 2012.
57. Kirane A, Toombs JE, Ostapoff K, et al: Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 18: 5031-5042, 2012.
58. Kong G, Kim EK, Kim WS, et al: Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 17: 914-921, 2002.
59. Ding XZ, Tong WG and Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 20: 2625-2631, 2000.
60. Eibl G, Bruemmer D, Okada Y, et al: PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 306: 887-897, 2003.
61. Colby JK, Klein RD, McArthur MJ, et al: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10: 782-796, 2008.
62. Furukawa F, Nishikawa A, Lee IS, et al: A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 104: 269-273, 2003.
63. Anderson KE, Johnson TW, Lazovich D and Folsom AR: Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94: 1168-1171, 2002.
64. Wenger FA, Kilian M, Achucarro P, et al: Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2: 54-60, 2002.
65. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64: 2030-2038, 2004.
66. Jacobs EJ, Connell CJ, Rodriguez C, et al: Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96: 524-528, 2004.
67. Schernhammer ES, Kang JH, Chan AT, et al: A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96: 22-28, 2004.
68. Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142, 2001.
69. Shi Q, Le X, Abbruzzese JL, et al: Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res 19: 1363-1371, 1999.
70. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
71. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
72. Lu Z, Li Y, Takwi A, et al: miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J 30: 57-67, 2011.
73. Liptay S, Weber CK, Ludwig L, et al: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746, 2003.
74. Fujioka S, Sclabas GM, Schmidt C, et al: Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354, 2003.
75. Hoffmann A and Baltimore D: Circuitry of nuclear factor kappaB signaling. Immunol Rev 210: 171-186, 2006.
76. Qing G and Xiao G: Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem 280: 9765-9768, 2005.
77. Carbone C and Melisi D: NF-κB as a target for pancreatic cancer therapy. Expert Opin Ther Targets 16 (Suppl 2): S1-S10, 2012.
78. Niu J, Li Z, Peng B and Chiao PJ: Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 279: 16452-16462, 2004.
79. Melisi D, Niu J, Chang Z, et al: Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res 7: 624-633, 2009.
80. Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112, 2009.
81. Kazal LA, Spicer DS and Brahinsky RA: Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 70: 3034-3040, 1948.
82. Witt H, Luck W, Hennies HC, et al: Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 25: 213-216, 2000.
83. Schneider A, Barmada MM, Slivka A, Martin JA and Whitcomb DC: Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 mutations. Scand J Gastroenterol 39: 903-904, 2004.
84. Chen JM, Mercier B, Audrezet MP, et al: Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology 120: 1061-1064, 2001.
85. Pfützer RH, Barmada MM, Brunskill AP, et al: SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 119: 615-623, 2000.
86. Kuwata K, Hirota M, Nishimori I, Otsuki M and Ogawa M: Mutational analysis of the pancreatic secretory trypsin inhibitor gene in familial and juvenile pancreatitis in Japan. J Gastroenterol 38: 365-370, 2003.
87. Ohmuraya M, Hirota M, Araki M, et al: Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice. Gastroenterology 129: 696-705, 2005.
88. Rebours V, Couvelard A, Sauvanet A, et al: Pancreatic intraepithelial neoplasia is associated with chronic pancreatitis due to serine protease inhibitor kazal type 1 and cystic fibrosis transmembrane conductance regulator mutations. Pancreas 39: 947-948, 2010.
89. Shimosegawa T, Kume K and Satoh K: Chronic pancreatitis and pancreatic cancer: prediction and mechanism. Clin Gastroenterol Hepatol 7 (11 Suppl): S23-S28, 2009.
90. Ogawa M, Matsuura N, Higashiyama K and Mori T: Expression of pancreatic secretory trypsin inhibitor in various cancer cells. Res Commun Chem Pathol Pharmacol 55: 137-140, 1987.
91. Ozaki N, Ohmuraya M, Hirota M, et al: Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 7: 1572-1581, 2009.
92. Ozaki N, Ohmuraya M, Ida S, et al: Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Sci: Mar 12, 2013 (Epub ahead of print).
93. Oikawa T, Hitomi J, Kono A, et al: Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int J Pancreatol 18: 15-23, 1995.
94. Korc M, Friess H, Yamanaka Y, et al: Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. Gut 35: 1468-1473, 1994.
95. Tonouchi A, Ohtsuka M, Ito H, et al: Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol 101: 1601-1610, 2006.
96. Gouyer V, Fontaine D, Dumont P, et al: Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 27: 4024-4033, 2008.
97. Lo YY and Cruz TF: Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem 270: 11727-11730, 1995.
98. Liou GY and Storz P: Reactive oxygen species in cancer. Free Radic Res 44: 479-496, 2010.
99. Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
100. Leung PS and Chan YC: Role of oxidative stress in pancreatic inflammation. Antioxid Redox Signal 11: 135-165, 2009.
101. Garcea G, Dennison AR, Steward WP and Berry DP: Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 5: 514-529, 2005.
102. Lau AT, He QY and Chiu JF: A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem J 382: 641-650, 2004.
103. Lau AT and Chiu JF: Proteomic and biochemical analyses of in vitro carcinogen-induced lung cell transformation: synergism between arsenic and benzo[a]pyrene. Proteomics 6: 1619-1630, 2006.
104. Barchowsky A, Dudek EJ, Treadwell MD and Wetterhahn KE: Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 21: 783-790, 1996.
105. Schoenberg MH, Birk D and Beger HG: Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr 62 (6 Suppl): 1306S-1314S, 1995.
106. Kadlubar FF, Anderson KE, Häussermann S, et al: Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res 405: 125-133, 1998.
107. Cullen JJ, Mitros FA and Oberley LW: Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas 26: 23-27, 2003.
108. Teoh ML, Sun W, Smith BJ, Oberley LW and Cullen JJ: Modulation of reactive oxygen species in pancreatic cancer. Clin Cancer Res 13: 7441-7450, 2007.
109. Benhar M, Engelberg D and Levitzki A: ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3: 420-425, 2002.
110. Martindale JL and Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1-15, 2002.
111. Leonard SS, Harris GK and Shi X: Metal-induced oxidative stress and signal transduction. Free Radic Biol Med 37: 1921-1942, 2004.
112. Shimojo Y, Akimoto M, Hisanaga T, et al: Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis 30: 143-154, 2013.
113. DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
114. Hossain MZ and Kleve MG: Nickel nanowires induced and reactive oxygen species mediated apoptosis in human pancreatic adenocarcinoma cells. Int J Nanomedicine 6: 1475-1485, 2011.
115. Lau ST, Lin ZX and Leung PS: Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br J Cancer 102: 583-593, 2010.
116. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Inves 117: 1175-1183, 2007.
117. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
118. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ and Ross JA: Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 21: 881-886, 2002.
119. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al: Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54: 683-689, 2009.
120. Miron N, Miron MM, Milea VG and Cristea V: Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum Arch Microbiol Immunol 69: 183-189, 2010.
121. Dima SO, Tanase C, Albulescu R, et al: An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 41: 1001-1007, 2012.
122. Matsuo Y, Takeyama H and Guha S: Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des 18: 2416-2419, 2012.
123. Maker AV, Katabi N, Qin LX, et al: Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 17: 1502-1508, 2011.
124. Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
125. Beg AA and Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996.
126. McDade TP, Perugini RA, Vittimberga FJ Jr, Carrigan RC and Callery MP: Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res 83: 56-61, 1999.
127. Baran B, Bechyne I, Siedlar M, et al: Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor - alpha. Eur J Cell Biol 88: 743-752, 2009.
128. Feurino LW, Zhang Y, Bharadwaj U, et al: IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther 6: 1096-1100, 2007.
129. Block KM, Hanke NT, Maine EA and Baker AF: IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas 41: 773-781, 2012.
130. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736, 2004.
131. Kamohara H, Takahashi M, Ishiko T, Ogawa M and Baba H: Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol 31: 627-632, 2007.
132. Hussain F, Wang J, Ahmed R, et al: The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 49: 134-140, 2010.
133. Le X, Shi Q, Wang B, et al: Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20: 935-946, 2000.
134. Xu X, Wang Y, Chen J, et al: High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg 16: 1493-1498, 2012.
135. Grote VA, Kaaks R, Nieters A, et al: Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 106: 1866-1874, 2012.
136. Schmieder A, Multhoff G and Radons J: Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 60: 514-521, 2012.
137. Bonifazi M, Gallus S, Bosetti C, et al: Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 19: 352-354, 2010.
138. Bradley MC, Hughes CM, Cantwell MM, et al: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer 102: 1415-1421, 2010.
139. Rothwell PM, Fowkes FG, Belch JF, et al: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41, 2011.